- Home
- CABA vs REFI Comparison
CABA vs REFI Comparison
Compare CABA & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- REFI
- Stock Information
- Founded
- CABA 2017
- REFI 2021
- Country
- CABA United States
- REFI United States
- Employees
- CABA N/A
- REFI N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- REFI Real Estate Investment Trusts
- Sector
- CABA Health Care
- REFI Real Estate
- Exchange
- CABA Nasdaq
- REFI Nasdaq
- Market Cap
- CABA 233.2M
- REFI 255.6M
- IPO Year
- CABA 2019
- REFI 2021
- Fundamental
- Price
- CABA $2.32
- REFI $12.67
- Analyst Decision
- CABA Strong Buy
- REFI Strong Buy
- Analyst Count
- CABA 8
- REFI 3
- Target Price
- CABA $13.50
- REFI $20.00
- AVG Volume (30 Days)
- CABA 5.3M
- REFI 93.4K
- Earning Date
- CABA 11-10-2025
- REFI 11-04-2025
- Dividend Yield
- CABA N/A
- REFI 16.23%
- EPS Growth
- CABA N/A
- REFI N/A
- EPS
- CABA N/A
- REFI 1.69
- Revenue
- CABA N/A
- REFI $54,287,847.00
- Revenue This Year
- CABA N/A
- REFI $11.43
- Revenue Next Year
- CABA N/A
- REFI $4.75
- P/E Ratio
- CABA N/A
- REFI $7.49
- Revenue Growth
- CABA N/A
- REFI N/A
- 52 Week Low
- CABA $0.99
- REFI $12.00
- 52 Week High
- CABA $5.46
- REFI $16.29
- Technical
- Relative Strength Index (RSI)
- CABA 44.66
- REFI 43.45
- Support Level
- CABA $2.30
- REFI $12.51
- Resistance Level
- CABA $2.67
- REFI $12.97
- Average True Range (ATR)
- CABA 0.33
- REFI 0.23
- MACD
- CABA -0.07
- REFI -0.00
- Stochastic Oscillator
- CABA 8.05
- REFI 27.54
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.